219
Participants
Start Date
October 8, 2017
Primary Completion Date
October 27, 2020
Study Completion Date
July 28, 2023
Enfortumab vedotin
Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
New York University (NYU) Cancer Institute, New York
Mount Sinai Medical Center, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
New York Oncology Hematology, P.C., Albany
James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Maryland Oncology Hematology, P.A., Rockville
Johns Hopkins Medical Center, Baltimore
Virginia Cancer Specialists, PC, Fairfax
University of Virginia, Charlottesville
Virginia Oncology Associates, Norfolk
Duke University Medical Center, Durham
Prisma Health, Greenville
Augusta University, Augusta
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Ocala Oncology Center, Ocala
Vanderbilt University Medical Center, Nashville
Norton Cancer Institute, St. Matthews Campus, Louisville
James Cancer Hospital / Ohio State University, Columbus
Cleveland Clinic, Cleveland
Karmanos Cancer Institute / Wayne State University, Detroit
Washington University in St Louis, St Louis
Texas Oncology - Baylor Sammons Cancer Center, Dallas
Houston Methodist Cancer Center, Houston
Texas Oncology - Austin Central, Austin
Rocky Mountain Cancer Centers - Aurora, Aurora
Mayo Clinic Arizona, Phoenix
Arizona Oncology Associates, PC - HAL, Goodyear
Arizona Oncology Associates, PC - HOPE, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
Keck Medical Center / University of Southern California, Los Angeles
Keck Medical Center / Newport Beach, Newport Beach
Chao Family Comprehensive Cancer Center University of California Irvine, Orange
University of California Irvine - Newport, Orange
Kaiser Permanente South San Francisco, South San Francisco
Kaiser Permanente San Francisco, San Francisco
Kaiser Permanente San Leandro, San Leandro
Kaiser Permanente Medical Center Northern California, Vallejo
Kaiser Permanente Walnut Creek, Walnut Creek
Kaiser Permanente Oakland, Oakland
Kaiser Permanente Santa Clara, Santa Clara
Kaiser Permanente San Jose, San Jose
Kaiser Permanente Roseville, Roseville
University of California Davis, Sacramento
Kaiser Permanente Sacramento, Sacramento
Northwest Cancer Specialists, P.C., Tigard
Alaska Urological Institute, Anchorage
Yale Cancer Center, New Haven
University of Chicago Medical Center, Chicago
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Seattle Cancer Care Alliance / University of Washington, Seattle
Site FR33001, Villejuif-Cedex-France
Site DE49004, Münster
Site DE49001, Tübingen
Site IT39001, Milan
Site IT39003, Terni
Site JP81001, Hirosaki
Site JP81004, Tsukuba
Site JP81002, Morioka
Site JP81003, Nigata
Site JP81008, Sayama
Site JP81006, Shinjuku-ku
Site JP81009, Ube
Site JP81005, Chiba
Site JP81011, Fukuoka
Site JP81012, Fukuoka
Site JP81007, Osaka
Site JP81010, Tokushima
Site NL31001, Amsterdam
Site KR82005, Daejeon
Site KR82003, Seongnam-si
Site KR82001, Seoul
Site KR82002, Seoul
Site KR82004, Seoul
Site ES34002, Barcelona
Site ES34005, Barcelona
Site ES34003, Santander
Site ES34004, Seville
Lead Sponsor
Seagen Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY